MO

Altria Group, Inc. (MO) - Q2 2024 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2024. Altria Group, Inc. is a leading tobacco company with a portfolio including combustible cigarettes (Marlboro), cigars (Black & Mild), moist smokeless tobacco (Copenhagen, Skoal), oral nicotine pouches (on!), and e-vapor products (NJOY). The company is executing a strategy to transition adult smokers to smoke-free products while maintaining its leadership in the U.S. tobacco market.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Net revenues decreased 3.6% year-over-year for the six months ended June 30, 2024, primarily due to lower shipment volumes in the smokeable products segment, partially offset by higher pricing and growth in oral tobacco products.
• Significant One-Time Gain: Reported net earnings increased 51.9% year-over-year, driven largely by a $2.7 billion pre-tax gain from the assignment of exclusive U.S. commercialization rights for the IQOS System to Philip Morris International (PMI) in April 2024.
• Asset Impairment: The company recorded a non-cash, pre-tax impairment charge of $354 million related to the Skoal trademark in the oral tobacco products segment due to declining sales volumes and competitive pressures from oral nicotine pouches.
• Investment Activity: In March 2024, Altria sold a portion of its investment in Anheuser-Busch InBev (ABI), generating approximately $2.4 billion in proceeds. These proceeds were used to fund accelerated share repurchases (ASR).
• Share Repurchases: The company repurchased approximately 54.1 million shares for an aggregate cost of $2.41 billion during the first six months of 2024.

Guidance, Outlook, and Risks

• 2028 Enterprise Goals: Altria targets mid-single-digit adjusted diluted EPS CAGR, a progressive dividend goal, and a debt-to-Consolidated EBITDA ratio of approximately 2.0x by 2028. It aims to double U.S. smoke-free net revenues to $5 billion by 2028.
• Regulatory Environment: The FDA issued Marketing Grant Orders (MGOs) for four NJOY menthol e-vapor products in June 2024, triggering a $250 million contingent payment obligation under the NJOY acquisition agreement. The FDA has indefinitely delayed a decision on a proposed menthol cigarette ban.
• Market Trends: The company notes significant growth in the e-vapor category (approx. 40% growth in H1 2024), driven largely by illicit disposable products, which is contributing to cross-category movement away from cigarettes. Inflation and discretionary income pressures continue to influence consumer purchasing behavior, favoring discount segments.
• Litigation: Significant tobacco-related litigation remains pending, including Engle progeny cases and e-vapor product litigation. The company recorded provisions for various settlements, including a $20 million provision for Native American tribe e-vapor settlements in Q2 2024.

Investor Verification Checklist

• IQOS Gain Realization: Verify the timing and tax implications of the $2.7 billion gain from the IQOS rights assignment and its impact on future comparability.
• Skoal Impairment Sensitivity: Review the assumptions used in the Skoal trademark impairment (discount rate, growth rate) and assess the risk of further impairments if volume declines accelerate.
• Illicit E-Vapor Impact: Monitor the company's ability to compete against illicit disposable e-vapor products, which are estimated to represent over 60% of the e-vapor category.
• NJOY Contingent Payments: Track the status of remaining contingent payments related to the NJOY acquisition, specifically regarding blueberry and watermelon flavor approvals.
• Dividend Sustainability: Confirm the company's ability to maintain its progressive dividend policy amidst declining combustible volumes and high capital return commitments (dividends + buybacks).